Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

7.205 +0.115 (+1.62%)
Streaming Delayed Price Updated: 11:06 AM EST, Dec 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Cramer Calls Tech Giant A 'Great' Long-Term Play, But In The Short Term It's Just 'Too Hot' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said British American Tobacco p.l.c. (NYSE: BTI) is a "cheap stock. I’ll tell you, I actually like some of the things that Philip Morris International... 
Via Benzinga
News headline image
3 Gene Testing Stocks to Buy Before They Take Off ↗
The future of gene testing is bright thanks to an aging population. Here are three companies leading the industry. 
Via InvestorPlace
News headline image
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and response 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Participate in Goldman Sachs Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Where Myriad Genetics Stands With Analysts ↗
 
Via Benzinga
News headline image
Where Myriad Genetics Stands With Analysts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 3, 2023 ↗
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
News headline image
Preview: Myriad Genetics's Earnings ↗
 
Via Benzinga
News headline image
Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces New $90 Million Asset-Based Credit Facility
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Why CohBar Shares Are Trading Lower By 161%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2023 ↗
 
Via Benzinga
News headline image
Lilium, Myriad Genetics And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session ↗
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
News headline image
Exact Sciences Serves Investors Exactly What They Wished For
Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The 
Via MarketBeat
News headline image
Myriad Genetics Earns 2023 Great Place to Work Certification™
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Why Atlassian Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Myriad Genetics to Participate in BofA Securities Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Release First Quarter Financial Results on May 3, 2023
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey
Medication failure leads 45% of respondents with depression and/or anxiety to turn to unhealthy coping mechanisms 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Intermountain Precision Genomics and Myriad Genetics Now Offer Solid Tumor Testing in All 50 States
About Intermountain Health Headquartered in Utah with locations in seven states and additional operations across the western U.S., www.intermountainhealth.org is a nonprofit system of 33 hospitals, 385... 
Via PRUnderground
News headline image
Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification
Intermountain Precision Genomics Laboratory receives certification from NYS Department of Health Clinical Laboratory Evaluation Program 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program
New program will increase access to affordable genetic testing while also helping to identify and elevate high-risk patient care 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket ↗
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it. 
Via InvestorPlace
News headline image
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
Strategic partnership offers a unique combination of diagnostic development and commercialization capabilities to the pharmaceutical industry 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.